{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T04:22:47Z","timestamp":1746591767906},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,20]]},"DOI":"10.7759\/cureus.64972","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T09:07:34Z","timestamp":1721466454000},"source":"Crossref","is-referenced-by-count":1,"title":["Combination of Radiation Therapy, Wim\u2019s Tumor 1 (WT1) Dendritic Cell Vaccine Therapy, and \u03b1-Galactosylceramide-Pulsed Dendritic Cell Vaccine Therapy for End-Stage Small Bowel Cancer"],"prefix":"10.7759","author":[{"given":"Hisashi","family":"Nagai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Karube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Koitabashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ouka","family":"Numata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yamahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Recent advances in the management of adenocarcinoma of the small intestine","volume":"3","author":"Overman MJ","year":"2009","unstructured":"Overman MJ. Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res. 2009, 3:90-6.","journal-title":"Gastrointest Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang Y","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020, 17:807-21. 10.1038\/s41423-020-0488-6","journal-title":"Cell Mol Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever MA","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, et al.. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009, 15:5323-37. 10.1158\/1078-0432.CCR-09-0737","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48412","article-title":"Radioimmunotherapy with WT1 dendritic cell vaccine for end-stage lung adenocarcinoma markedly shrinks tumors","volume":"15","author":"Nagai H","year":"2023","unstructured":"Nagai H, Karube R, Zhao F. Radioimmunotherapy with WT1 dendritic cell vaccine for end-stage lung adenocarcinoma markedly shrinks tumors. Cureus. 2023, 15:e48412. 10.7759\/cureus.48412","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49221","article-title":"Delayed-type hypersensitivity: an excellent indicator of anti-tumor immunity with Wilms' tumor 1 (WT1) dendritic cell vaccine therapy","volume":"15","author":"Nagai H","year":"2023","unstructured":"Nagai H, Karube R. Delayed-type hypersensitivity: an excellent indicator of anti-tumor immunity with Wilms' tumor 1 (WT1) dendritic cell vaccine therapy. Cureus. 2023, 15:e49221. 10.7759\/cureus.49221","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47320","article-title":"WT1 dendritic cell vaccine therapy improves immune profile and prolongs progression-free survival in end-stage lung cancer","volume":"15","author":"Nagai H","year":"2023","unstructured":"Nagai H, Karube R. WT1 dendritic cell vaccine therapy improves immune profile and prolongs progression-free survival in end-stage lung cancer. Cureus. 2023, 15:e47320. 10.7759\/cureus.47320","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.57144","article-title":"Immunoradiation therapy for end-stage undifferentiated cervical cancer that restored sensitivity to chemotherapy and resulted in the disappearance of the cancer","volume":"16","author":"Nagai H","year":"2024","unstructured":"Nagai H. Immunoradiation therapy for end-stage undifferentiated cervical cancer that restored sensitivity to chemotherapy and resulted in the disappearance of the cancer. Cureus. 2024, 16:e57144. 10.7759\/cureus.57144","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00384","article-title":"Novel approaches to exploiting invariant NKT cells in cancer immunotherapy","volume":"9","author":"Wolf BJ","year":"2018","unstructured":"Wolf BJ, Choi JE, Exley MA. Novel approaches to exploiting invariant NKT cells in cancer immunotherapy. Front Immunol. 2018, 9:384. 10.3389\/fimmu.2018.00384","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12658","article-title":"Radiotherapy-immunotherapy combinations - perspectives and challenges","volume":"14","author":"Mondini M","year":"2020","unstructured":"Mondini M, Levy A, Meziani L, Milliat F, Deutsch E. Radiotherapy-immunotherapy combinations - perspectives and challenges. Mol Oncol. 2020, 14:1529-37. 10.1002\/1878-0261.12658","journal-title":"Mol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00156","article-title":"Novel approaches to improve the efficacy of immuno-radiotherapy","volume":"9","author":"Shevtsov M","year":"2019","unstructured":"Shevtsov M, Sato H, Multhoff G, Shibata A. Novel approaches to improve the efficacy of immuno-radiotherapy. Front Oncol. 2019, 9:156. 10.3389\/fonc.2019.00156","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01126","article-title":"\u03b1-GalCer and iNKT cell-based cancer immunotherapy: realizing the therapeutic potentials","volume":"10","author":"Zhang Y","year":"2019","unstructured":"Zhang Y, Springfield R, Chen S, et al.. \u03b1-GalCer and iNKT cell-based cancer immunotherapy: realizing the therapeutic potentials. Front Immunol. 2019, 10:1126. 10.3389\/fimmu.2019.01126","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205174","article-title":"The current landscape of NKT cell immunotherapy and the hills ahead","volume":"13","author":"Nelson A","year":"2021","unstructured":"Nelson A, Lukacs JD, Johnston B. The current landscape of NKT cell immunotherapy and the hills ahead. Cancers (Basel). 2021, 13:5174. 10.3390\/cancers13205174","journal-title":"Cancers (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0718-6","article-title":"Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy","volume":"7","author":"Menon H","year":"2019","unstructured":"Menon H, Chen D, Ramapriyan R, et al.. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer. 2019, 7:237. 10.1186\/s40425-019-0718-6","journal-title":"J Immunother Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria S","year":"2021","unstructured":"Demaria S, Guha C, Schoenfeld J, et al.. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?. J Immunother Cancer. 2021, 9:e002038. 10.1136\/jitc-2020-002038","journal-title":"J Immunother Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/273087-combination-of-radiation-therapy-wims-tumor-1-wt1-dendritic-cell-vaccine-therapy-and--galactosylceramide-pulsed-dendritic-cell-vaccine-therapy-for-end-stage-small-bowel-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T09:07:38Z","timestamp":1721466458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/273087-combination-of-radiation-therapy-wims-tumor-1-wt1-dendritic-cell-vaccine-therapy-and--galactosylceramide-pulsed-dendritic-cell-vaccine-therapy-for-end-stage-small-bowel-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.64972","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,20]]}}}